Cytokeratin 4 Antibody (0.N.344): sc-70920

Cytokeratin 4 Antibody (0.N.344) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 4 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Cytokeratin 4 is a member of the cytokeratin family, which plays a crucial role in maintaining the structural integrity of epithelial cells. Anti-Cytokeratin 4 antibody (0.N.344) targets proteins primarily located in the differentiated layers of the mucosal and esophageal epithelia, where Cytokeratin 4 contributes to the mechanical resilience of these tissues. Cytokeratin 4 is essential for the proper functioning of epithelial barriers, helping to protect against physical and chemical stressors. Additionally, Cytokeratin 4 expression, along with Cytokeratin 13, indicates the differentiation status of epithelial cells, making Cytokeratin 4 a valuable marker in the study of various epithelial malignancies. Cytokeratin 4 monoclonal antibody (0.N.344) enables researchers to gain insights into both normal physiology and disease states, enhancing our understanding of epithelial biology and pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 4 Antibody (0.N.344) References:

1. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues.  |  Hourihan, RN., et al. 2003. Anticancer Res. 23: 161-5. PMID: 12680208
2. Isolation and characterization of cultured human conjunctival goblet cells.  |  Shatos, MA., et al. 2003. Invest Ophthalmol Vis Sci. 44: 2477-86. PMID: 12766046
3. Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma.  |  Takikita, M., et al. 2011. Anticancer Res. 31: 945-52. PMID: 21498718
4. Mass spectrometry-based salivary proteomics for the discovery of head and neck squamous cell carcinoma.  |  Jarai, T., et al. 2012. Pathol Oncol Res. 18: 623-8. PMID: 22350791
5. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)-based nanofibrous scaffolds to support functional esophageal epithelial cells towards engineering the esophagus.  |  Kuppan, P., et al. 2014. J Biomater Sci Polym Ed. 25: 574-93. PMID: 24502395
6. In vitro evaluation of bi-layer silk fibroin scaffolds for gastrointestinal tissue engineering.  |  Franck, D., et al. 2014. J Tissue Eng. 5: 2041731414556849. PMID: 25396043
7. Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation.  |  Enokida, T., et al. 2017. Oncotarget. 8: 61786-61799. PMID: 28977904
8. Evaluation of molecules or extracts modulating seborrhea and its consequences, using normal human culture of sebocytes and keratinocytes, skin explants models and in vivo methods: a case study.  |  Mondon, P., et al. 2017. J Cosmet Sci. 68: 183-194. PMID: 29619942
9. Clinicocytopathological spectrum, including uncommon forms, of nine cases of chordomas with immunohistochemical results, including brachyury immunostaining: A single institutional experience.  |  Rekhi, B. and Karmarkar, S. 2019. Cytopathology. 30: 229-235. PMID: 30218622
10. Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic acid. A clinical and immunohistochemical study.  |  Steijlen, PM., et al. 1993. Arch Dermatol Res. 285: 221-6. PMID: 7688204

The preferred Cytokeratin 4 antibody is Cytokeratin 4 Antibody (6B10): sc-52321.